Share Price and Basic Stock Data
Last Updated: December 18, 2025, 9:31 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Krebs Biochemicals & Industries Ltd operates in the pharmaceuticals sector, a domain that often demands consistent innovation and robust supply chain management. The company reported a market capitalization of ₹144 Cr and a recent stock price of ₹66.7. Over the past quarters, Krebs has displayed a volatile revenue trajectory. For instance, sales peaked at ₹20.94 Cr in September 2022 but subsequently dipped to ₹9.09 Cr by December 2022. The trend has shown some recovery, with revenues rising to ₹14.89 Cr in September 2023. However, the trailing twelve months (TTM) revenue stands at ₹36 Cr, indicating a decline from previous fiscal years, where revenues were ₹60 Cr in FY 2022 and ₹54 Cr in FY 2023. This fluctuation might raise questions about the company’s operational resilience and market demand for its products.
Profitability and Efficiency Metrics
The profitability metrics for Krebs continue to present a challenging picture. The company has reported negative net profits across multiple quarters, culminating in a net loss of ₹27 Cr in FY 2025. The operating profit margin (OPM) remains deeply in the red, standing at -38.14%. This is concerning, especially when compared to industry benchmarks, where positive margins are typically expected. The interest coverage ratio (ICR) of 2.42x suggests that while the company can meet its interest obligations, the negative profitability raises questions about sustainable growth. Moreover, a cash conversion cycle of -795 days indicates that Krebs is struggling to convert its investments in inventory and receivables into cash efficiently, which could further exacerbate its liquidity challenges.
Balance Sheet Strength and Financial Ratios
Krebs’ balance sheet presents a mixed picture. The company has reported total borrowings of ₹212 Cr, which is concerning given that its reserves are negative at ₹168 Cr. This raises the debt-to-equity ratio to a troubling level, emphasizing the financial strain Krebs is under. The price-to-book value ratio stands at -0.98x, suggesting that the market values the company’s assets less than its liabilities, which often signals distress. Furthermore, the current ratio of 0.09 indicates a significant liquidity crunch, as it suggests that Krebs may struggle to meet short-term obligations. The company must address these balance sheet issues to regain investor confidence and ensure long-term viability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Krebs Biochemicals reveals a strong promoter holding of 72.74%, which can be a positive indicator of commitment from the management. However, foreign institutional investment (FIIs) is minimal at 0.50%, reflecting a lack of confidence from external investors. The public holds 26.76% of the shares, but the declining number of shareholders—from 9,294 in December 2022 to 8,912 in March 2025—suggests waning interest among retail investors. This shift could indicate growing concerns regarding the company’s financial health and future prospects. While the strong promoter stake could provide some stability, the lack of broader investor support may limit the company’s ability to raise capital or attract new investments.
Outlook, Risks, and Final Insight
Looking ahead, Krebs Biochemicals faces a challenging landscape. The company’s ongoing financial losses, coupled with a negative cash conversion cycle, indicate substantial operational inefficiencies that need to be addressed urgently. Risks include continued liquidity pressures stemming from high debt levels and a lack of profitability, which could hinder growth initiatives. Additionally, the minimal foreign investment may limit the company’s access to the capital needed for recovery. Investors should weigh these factors carefully. While the established promoter holding provides some assurance, the overall financial instability could lead to further declines in shareholder value. This scenario necessitates a cautious approach for potential investors, as the path to recovery seems fraught with challenges that require strategic operational overhauls and improved cash management practices.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,222 Cr. | 389 | 479/192 | 87.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.2 Cr. | 32.9 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,007.32 Cr | 1,144.50 | 52.26 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Krebs Biochemicals & Industries Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.64 | 20.94 | 9.09 | 11.46 | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 |
| Expenses | 16.91 | 22.84 | 12.07 | 16.08 | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 |
| Operating Profit | -6.27 | -1.90 | -2.98 | -4.62 | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 |
| OPM % | -58.93% | -9.07% | -32.78% | -40.31% | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% |
| Other Income | 0.13 | 0.27 | 0.02 | 0.19 | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 |
| Interest | 0.30 | 0.74 | 0.90 | 1.03 | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 |
| Depreciation | 1.69 | 1.69 | 1.69 | 1.48 | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 |
| Profit before tax | -8.13 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% |
| Net Profit | -8.14 | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 |
| EPS in Rs | -3.78 | -1.88 | -2.57 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 |
Last Updated: August 20, 2025, 8:00 am
Below is a detailed analysis of the quarterly data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.48 Cr.. The value appears to be declining and may need further review. It has decreased from 6.10 Cr. (Mar 2025) to 5.48 Cr., marking a decrease of 0.62 Cr..
- For Expenses, as of Jun 2025, the value is 7.57 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.51 Cr. (Mar 2025) to 7.57 Cr., marking a decrease of 3.94 Cr..
- For Operating Profit, as of Jun 2025, the value is -2.09 Cr.. The value appears strong and on an upward trend. It has increased from -5.41 Cr. (Mar 2025) to -2.09 Cr., marking an increase of 3.32 Cr..
- For OPM %, as of Jun 2025, the value is -38.14%. The value appears strong and on an upward trend. It has increased from -88.69% (Mar 2025) to -38.14%, marking an increase of 50.55%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.34 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Jun 2025, the value is 1.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.61 Cr. (Mar 2025) to 1.65 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Jun 2025, the value is 1.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.57 Cr. (Mar 2025) to 1.60 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is -5.33 Cr.. The value appears strong and on an upward trend. It has increased from -8.25 Cr. (Mar 2025) to -5.33 Cr., marking an increase of 2.92 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 0.24% (Mar 2025) to 0.00%, marking a decrease of 0.24%.
- For Net Profit, as of Jun 2025, the value is -5.32 Cr.. The value appears strong and on an upward trend. It has increased from -8.27 Cr. (Mar 2025) to -5.32 Cr., marking an increase of 2.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.47. The value appears strong and on an upward trend. It has increased from -3.84 (Mar 2025) to -2.47, marking an increase of 1.37.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:04 am
| Metric | Sep 2014n n 15m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0 | -0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 27 |
| Expenses | 4 | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 42 |
| Operating Profit | -4 | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -15 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -55% | ||
| Other Income | 0 | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | -0 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| Tax % | 10% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 0% | |
| Net Profit | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| EPS in Rs | -3.78 | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -12.75 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -12.50% | -11.11% | -45.00% | 3.45% | -60.71% | 44.44% | 20.00% | -35.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.50% | 1.39% | -33.89% | 48.45% | -64.16% | 105.16% | -24.44% | -55.00% |
Krebs Biochemicals & Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -10% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 12% |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -4% |
| 3 Years: | -19% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 9:20 am
Balance Sheet
Last Updated: December 10, 2025, 2:59 am
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -6 | 9 | -0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -179 |
| Borrowings | 93 | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 219 |
| Other Liabilities | 41 | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 106 |
| Total Liabilities | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
| Fixed Assets | 58 | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 146 |
| CWIP | 0 | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 80 | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
Below is a detailed analysis of the balance sheet data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is -179.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -168.00 Cr. (Mar 2025) to -179.00 Cr., marking a decline of 11.00 Cr..
- For Borrowings, as of Sep 2025, the value is 219.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 212.00 Cr. (Mar 2025) to 219.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 106.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 106.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 168.00 Cr.. The value appears to be improving (decreasing). It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 146.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 146.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
However, the Borrowings (219.00 Cr.) are higher than the Reserves (-179.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2014n n 15m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -43.00 | -56.00 | -64.00 | -63.00 | -85.00 | -129.00 | -177.00 | -199.00 | -203.00 | -227.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | ||
| Inventory Days | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | ||
| Days Payable | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | ||
| Cash Conversion Cycle | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | ||
| Working Capital Days | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | ||
| ROCE % | -4% | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Diluted EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Cash EPS (Rs.) | -9.39 | -6.01 | -8.41 | -17.73 | -11.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Revenue From Operations / Share (Rs.) | 20.09 | 23.39 | 24.18 | 27.69 | 27.37 |
| PBDIT / Share (Rs.) | -6.64 | -3.84 | -7.03 | -15.23 | -8.64 |
| PBIT / Share (Rs.) | -9.74 | -6.97 | -10.07 | -18.15 | -11.25 |
| PBT / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| Net Profit / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| PBDIT Margin (%) | -33.06 | -16.40 | -29.07 | -55.00 | -31.57 |
| PBIT Margin (%) | -48.50 | -29.82 | -41.65 | -65.55 | -41.11 |
| PBT Margin (%) | -62.16 | -39.12 | -47.36 | -74.58 | -52.80 |
| Net Profit Margin (%) | -62.19 | -39.12 | -47.36 | -74.58 | -52.80 |
| Return on Capital Employeed (%) | -32.07 | -12.92 | -17.25 | -35.02 | -19.88 |
| Return On Assets (%) | -15.93 | -11.07 | -14.11 | -23.45 | -17.81 |
| Long Term Debt / Equity (X) | -0.21 | -0.44 | -0.43 | -0.03 | -2.35 |
| Total Debt / Equity (X) | -0.56 | -0.53 | -0.53 | -0.17 | -2.35 |
| Asset Turnover Ratio (%) | 0.24 | 0.28 | 0.28 | 0.34 | 0.36 |
| Current Ratio (X) | 0.09 | 0.28 | 0.32 | 0.45 | 0.44 |
| Quick Ratio (X) | 0.04 | 0.12 | 0.08 | 0.12 | 0.09 |
| Inventory Turnover Ratio (X) | 5.47 | 0.49 | 0.81 | 2.19 | 1.62 |
| Interest Coverage Ratio (X) | -2.42 | -1.76 | -5.10 | -6.09 | -2.70 |
| Interest Coverage Ratio (Post Tax) (X) | -3.56 | -3.21 | -7.30 | -7.26 | -3.52 |
| Enterprise Value (Cr.) | 356.07 | 324.85 | 304.75 | 451.99 | 274.16 |
| EV / Net Operating Revenue (X) | 8.22 | 6.44 | 5.85 | 7.57 | 5.11 |
| EV / EBITDA (X) | -24.86 | -39.27 | -20.10 | -13.76 | -16.17 |
| MarketCap / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| Price / BV (X) | -0.98 | -1.10 | -1.22 | -4.12 | -4.08 |
| Price / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| EarningsYield | -0.18 | -0.14 | -0.20 | -0.14 | -0.16 |
After reviewing the key financial ratios for Krebs Biochemicals & Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Cash EPS (Rs.), as of Mar 25, the value is -9.39. This value is below the healthy minimum of 3. It has decreased from -6.01 (Mar 24) to -9.39, marking a decrease of 3.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.09. It has decreased from 23.39 (Mar 24) to 20.09, marking a decrease of 3.30.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -6.64. This value is below the healthy minimum of 2. It has decreased from -3.84 (Mar 24) to -6.64, marking a decrease of 2.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -9.74. This value is below the healthy minimum of 0. It has decreased from -6.97 (Mar 24) to -9.74, marking a decrease of 2.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 0. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 2. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For PBDIT Margin (%), as of Mar 25, the value is -33.06. This value is below the healthy minimum of 10. It has decreased from -16.40 (Mar 24) to -33.06, marking a decrease of 16.66.
- For PBIT Margin (%), as of Mar 25, the value is -48.50. This value is below the healthy minimum of 10. It has decreased from -29.82 (Mar 24) to -48.50, marking a decrease of 18.68.
- For PBT Margin (%), as of Mar 25, the value is -62.16. This value is below the healthy minimum of 10. It has decreased from -39.12 (Mar 24) to -62.16, marking a decrease of 23.04.
- For Net Profit Margin (%), as of Mar 25, the value is -62.19. This value is below the healthy minimum of 5. It has decreased from -39.12 (Mar 24) to -62.19, marking a decrease of 23.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is -32.07. This value is below the healthy minimum of 10. It has decreased from -12.92 (Mar 24) to -32.07, marking a decrease of 19.15.
- For Return On Assets (%), as of Mar 25, the value is -15.93. This value is below the healthy minimum of 5. It has decreased from -11.07 (Mar 24) to -15.93, marking a decrease of 4.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0.2. It has increased from -0.44 (Mar 24) to -0.21, marking an increase of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.56. This value is within the healthy range. It has decreased from -0.53 (Mar 24) to -0.56, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.24. It has decreased from 0.28 (Mar 24) to 0.24, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 1.5. It has decreased from 0.28 (Mar 24) to 0.09, marking a decrease of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.12 (Mar 24) to 0.04, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.47. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 5.47, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 3. It has decreased from -1.76 (Mar 24) to -2.42, marking a decrease of 0.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3.56. This value is below the healthy minimum of 3. It has decreased from -3.21 (Mar 24) to -3.56, marking a decrease of 0.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 356.07. It has increased from 324.85 (Mar 24) to 356.07, marking an increase of 31.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.22. This value exceeds the healthy maximum of 3. It has increased from 6.44 (Mar 24) to 8.22, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is -24.86. This value is below the healthy minimum of 5. It has increased from -39.27 (Mar 24) to -24.86, marking an increase of 14.41.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For Price / BV (X), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 1. It has increased from -1.10 (Mar 24) to -0.98, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For EarningsYield, as of Mar 25, the value is -0.18. This value is below the healthy minimum of 5. It has decreased from -0.14 (Mar 24) to -0.18, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Krebs Biochemicals & Industries Ltd:
- Net Profit Margin: -62.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -32.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.26)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.56
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -62.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kothapalli Village, Kasimkota Mandal, Anakapalli Dist. Andhra Pradesh 531031 | investors@krebsbiochem.com www.krebsbiochem.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. R T Ravi | Chairman & Non-Exe.Director |
| Mr. Manish Kumar Jain | Managing Director & CEO |
| Mr. P K Bhattacharyya | Non Executive Director |
| Mr. Avinash Ravi | Non Executive Director |
| Mr. P M Kathariya | Independent Director |
| Ms. Dipti Shah | Independent Director |
| Mr. Satya Prakash Chigurupati | Independent Director |
| Mr. Sumanth Karlapudi | Independent Director |
FAQ
What is the intrinsic value of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd's intrinsic value (as of 18 December 2025) is 134.40 which is 97.36% higher the current market price of 68.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 146 Cr. market cap, FY2025-2026 high/low of 114/63.6, reserves of ₹-179 Cr, and liabilities of 168 Cr.
What is the Market Cap of Krebs Biochemicals & Industries Ltd?
The Market Cap of Krebs Biochemicals & Industries Ltd is 146 Cr..
What is the current Stock Price of Krebs Biochemicals & Industries Ltd as on 18 December 2025?
The current stock price of Krebs Biochemicals & Industries Ltd as on 18 December 2025 is 68.1.
What is the High / Low of Krebs Biochemicals & Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Krebs Biochemicals & Industries Ltd stocks is 114/63.6.
What is the Stock P/E of Krebs Biochemicals & Industries Ltd?
The Stock P/E of Krebs Biochemicals & Industries Ltd is .
What is the Book Value of Krebs Biochemicals & Industries Ltd?
The Book Value of Krebs Biochemicals & Industries Ltd is 73.2.
What is the Dividend Yield of Krebs Biochemicals & Industries Ltd?
The Dividend Yield of Krebs Biochemicals & Industries Ltd is 0.00 %.
What is the ROCE of Krebs Biochemicals & Industries Ltd?
The ROCE of Krebs Biochemicals & Industries Ltd is 30.1 %.
What is the ROE of Krebs Biochemicals & Industries Ltd?
The ROE of Krebs Biochemicals & Industries Ltd is %.
What is the Face Value of Krebs Biochemicals & Industries Ltd?
The Face Value of Krebs Biochemicals & Industries Ltd is 10.0.